Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (13944)	7/4/2000 12:09:34 AM
From: Cacaito	Respond to of 17367

Blue,you are not up to the challenge,but Gw task was easier! In the three LARGE HUMAN studies, 400 + 1000 + 400 for a total of 1800 subjects, there was antibiotic plus rbpi21 use! NO SYNERGY has been proven! The value of anticd11a is atractive and already way built up in the price! If Baxter go ahead for abdominal infections, or real proven gram negative sepsis and PAY$ a large pivotal study (some $100M in expenses) I will trust baxter again. Let's see what the bax is up (or down)to!, nothing yet after more than 4 months of involvement.

To: Bluegreen who wrote (13944)	7/4/2000 12:34:18 AM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Chiron's baboons also got better: ""Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB Chiron Corporation, Emeryville, California 94608. This study was designed to test the hypothesis that tissue factor pathway inhibitor (TFPI) plays a significant role in vivo in regulating coagulation that results from exposure of blood to tissue factor after vascular injury as in the case of gram negative sepsis. Highly purified recombinant TFPI (6 mg/kg) was administered either 30 min or 4 h after the start of a lethal intravenous Escherichia coli infusion in baboons. Early posttreatment of TFPI resulted in (a) permanent seven-day survivors (5/5) with significant improvement in quality of life, while the mean survival time for the controls (5/5) was 39.9 h (no survivors); and (b) significant attenuations of the coagulation response and various measures of cell injury, with significant reductions in pathology observed in E. coli sepsis target organs, including kidneys, adrenals, and lungs. TFPI administration did not affect the reduction in mean systemic arterial pressure, the increases in respiration and heart rate, or temperature changes associated with the bacterial infusion. TFPI treated E. coli infected baboons had significantly lower IL-6 levels than their phosphate buffered saline-treated controls, however tumor necrosis factor levels were similarly elevated in both groups. In contrast to the earlier 30-min treatment, the administration of TFPI at 4 h, i.e., 240 min, after the start of bacterial infusion resulted in prolongation of survival time, with 40% survival rate (2/5) and some attenuation of the coagulopathic response, especially in animals in which fibrinogen levels were above 10% of normal at the time of TFPI administration. Results provide evidence for the significance of tissue factor and tissue factor pathway inhibitor in bacterial sepsis, and suggest a role for blood coagulation in the regulation of the inflammatory response."" And Chiron is also in human phase III.